Conditions: Non-small Cell Lung Cancer
Keywords: Lung cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 51
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.

Detailed description:

Arms:
arm 1: Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond.

Interventions: intervention 1: Pertuzumab
Intervention descriptions: intervention 1: Pertuzumab was supplied as a single-use liquid formulation.

Protocol document: